Skip to main content

MidEuropa nabywa większościowy pakiet udziałów w Optegra


MidEuropa ogłosiła dziś, że zawarła ostateczną umowę nabycia większościowego pakietu udziałów w Optegra Eye Health Care ("Optegra" lub "Spółka"), wiodącej europejskiej platformie okulistycznej działającej w Polsce, Czechach, na Słowacji i w Wielkiej Brytanii.

Źródło: https://mideuropa.com/

29 listopada 2022

MidEuropa announced today that it has entered into a definitive agreement to acquire a majority stake in Optegra Eye Health Care (“Optegra” or the “Company”), a leading European ophthalmology platform operating in Poland, Czech Republic, Slovakia and the UK. The Company is led by an experienced management team who are reinvesting alongside MidEuropa and the current sponsor, H2 Equity Partners. The transaction, which is subject to customary competition and regulatory approvals, is expected to complete in the first half of 2023.

Optegra is offering a wide range of procedures including cataract, AMD, and vision correction for both public and private patients. The Company operates 29 highly integrated state-of-the art facilities and performs over 100k surgical procedures per year with a focus on industry-leading clinical outcomes and outstanding patient experience.

Pawel Malicki, Principal at MidEuropa, commented:

“Optegra is a fast-growing European healthcare player ideally positioned to deliver organic growth within its current footprint and expand into new geographies. We have closely followed Optegra’s development over the past few years and are impressed with its progress and excited to work with the management and H2 Equity Partners in building a pan-European ophthalmology champion.”

Dr. Peter Byloos, CEO of Optegra, commented:

“Optegra has a proven track record of delivering outstanding clinical outcomes and patient service, enabled by highly standardized pathways. We have built a strong foundation with H2 Equity Partners and we look forward to welcoming MidEuropa to accelerate our expansion and continue our strong engagement with our doctors, clinical teams and staff.”

Robert Knorr, Managing Partner of MidEuropa, commented:

“Our investment in Optegra demonstrates the firm’s continued focus on attractive and growth-oriented healthcare opportunities. MidEuropa has a strong track record in building and exiting national and regional healthcare leaders across the Central European region. We look forward to contributing our regional and sector experience to Optegra.”

The transaction was executed by Pawel Malicki, Eugeniu Prodan, David Nemcek and Ivo Cavrak.

MidEuropa was advised by Moelis (M&A), White & Case (legal), LEK (commercial), PwC (financial, tax and IT), and Houlihan Lokey (financing advisory).

H2 Equity Partners was advised by Lincoln International (M&A), Eversheds Sutherland (legal), Mansfield Advisors (commercial), PwC (financial), Grant Thornton (tax), and Diligize (IT).